CSMG Technologies, Inc (fka CTGI)

[lowman]

Again (and again, and again, if I must!):

Use this link to send LTC comments to JAMA (Journal of American Medical Association)

http://jama.ama-assn.org/cgi/feedback

Subject: Live tissue welding, 3rd generation technology

Category: General editorial question

Use this as a form letter or create your own. Either way, JUST SEND SOMETHING!

When doing so, also, do not send as though you are an investor (lest ye sound like you are 'selling' something), but rather simply someone who would feel much more comfortable on the surgery room table, if you knew this technology was being used on you. Please do NOT even include the CTGI trading symbol (JAMA is simply not concerned with that aspect of CSMG Technologies).

_____________________________________________________________________________


To the Editor:

I would like to bring to the Editor's attention the recent FDA approved (July 31, 2008) 3rd generation technology of live tissue welding.

3rd generation technology is often the 'final' generation of technology that the given area of such technology will be used

This recently (FDA) approved cutting-edge tissue welding technology 'goes where no others have gone before', performing smokeless, scarless, near bloodless surgery, and has been perfected to such extents that it now cuts present surgery room time down by as much as 50% as well as cutting present healing time down by as much as 50% (or more). Infections are also now minimized, and bodily rejection related to glues and/or sealants are now eliminated.

This 3rd generation tissue welding tecnhology comes to the U.S. from Ukraine, where it has already been used in over 10,000 human surgeries, in 80+ different types of procedures, ranging from tubal ligation reversals (increasing previous success rates of approx 15% to present success rates of approx. 80%), to lung resections, to spleen repair, etc.

This newer form of tissue welding has already even caught the interest of veterinarian associations.

In a day and age where quality, untainted, or rare blood can be difficult to find, near bloodless surgery becomes more attractive than ever, both, to the patient/surgeon, and to the insuring healthcare provider, if there is one. Also, where blood-transfusions is necessary, less lawsuits will occur, since less blood used means less risk of using 'bad blood'.

In a day and age where scarless surgery can be appreciated more than ever, the smokeless nature of LTC (Live Tissue Connect), which leaves no burned tissue, becomes invaluable to both the patient and the surgeon, and opens up a wider range of application, from cosmetic (breast implants, cesarian sections) to invasive surgery (spleen, lung, etc.)

In a day and age where healthcare costs have grown to astronomical levels, insurance companies will welcome LTC for the obvious surgery room savings as well as savings on shorter hospital room stays and other fronts (no follow-up visits for stitch removal, etc.).

Outlined here is only a rough idea of the virtues of this 3rd generation disruptive technology, and it is my belief that the medical community as a whole, could appreciate learning more about LTC, considering it for every day applications. The JAMA would be the most appropriate venue for announcing to the medical community and the world, the advent of this latest FDA approved development in disruptive surgical practices.

This disruptive surgical technology has been brought to us from Ukraine, by CSMG Technologies.


Contact info:

CSMG Technologies
501 North Shoreline Dr. Ste. 701 N.
Corpus Christi, TX. 78471

Pres/CEO Donald S. Robbins
Tel: [phone]



Thank you for taking the time to consider this request.



XXXXXXX X. XXXXXXXXXX